AMPAC re-opens 50,000 gallon API facility in Virginia

By Maggie Lynch

- Last updated on GMT

(Image: Getty/PBFloyd)
(Image: Getty/PBFloyd)

Related tags API facility Investment Ampac Manufacturing analytical

After being acquired by SK Holdings, AMPAC re-opens its API manufacturing facility in Virginia as part of a growing investment in its US capabilities.

AMPAC Fine Chemicals (AFC) re-opened its manufacturing operations at its active pharmaceutical ingredient (API) facility in Petersburg, US, after the site saw infrastructure refurbishment.

According to AFC, the pharmaceutical ingredients manufactured at the plant will be for pharmaceutical companies across the US and will be used in the production of treatments for central nervous system deficiencies, cancer, and epilepsy.

The expansion of the US-based company’s operations comes shortly after it was acquired as a portfolio company by SK holdings, an investment holding company of the South Korean SK Group.

The Petersburg site encompasses around 200 acres of the city’s industrial complex and has a 50,000-gallon capacity. With the re-opening, 100 jobs are expected to generate over the next few years.

AFC president and CEO, Aslam Malik, said in a statement that the re-opening of the plant demonstrates the company’s interest in employing more local residents, its growing investment in the US, and to create opportunities to develop community partnerships.

The company has operations in La Porte, Texas, Petersburg, Virginia, and both Rancho Cordova and El Dorado Hills, California. Its global offerings extend beyond technology platforms for API production including, continuous processes and industrial scale chromatographic separation, highly potent compound manufacturing, and analytical services.

Related news

Show more

Related products

A Guide Through the API Drug Development Pipeline

A Guide Through the API Drug Development Pipeline

Content provided by Lonza Small Molecules | 11-Jul-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

Related suppliers

Follow us


View more